Abstract
Chikungunya virus (CHIKV) is a mosquito-borne Alphavirus that has already infected millions of people in recent large-scale epidemics in Africa, the islands of the Indian Ocean, South and Southeast Asia, and northern Italy. The infection is still ongoing in many countries, such as India. Although the fatal rate is approximately 0.1 % in the La Réunion outbreak, it causes painful arthritis-like symptoms that can last for months or even years. Currently, neither vaccine nor approved antiviral therapy exists to protect humans from chikungunya infection. Therefore, there is an urgent unmet medical need for the development of antiviral drugs for pre-exposure prophylaxis and/or treatment of chikungunya infections. In this chapter, we describe a fully validated ATP/luminescence assay that is effective for high-throughput screening of CHIKV inhibitors. Protocols for growing CHIKV stocks and generating drug-resistant viral variants for modes of action studies of compounds are also described.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Schwartz O, Albert M (2010) Biology and pathogenesis of chikungunya virus. Nat Rev Microbiol 8(7):491–500
Pialoux G, Gaüzère B, Jauréguiberry S, Strobel M (2007) Chikungunya, an epidemic arbovirosis. Lancet Infect Dis 7(5):319–327
Gould EA, Coutard B, Malet H et al (2010) Understanding the alphaviruses: recent research on important emerging pathogens and progress towards their control. Antiviral Res 87(2):111–124
Hoarau J, Bandjee M et al (2010) Persistent chronic inflammation and infection by chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol 184:5914–5927
Labadie K, Larcher T et al (2010) Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest 120(3):894–906
Gong E, Ivens T, Bonfanti JF, Kraus G (2012) Method for identifying inhibitors against chikungunya virus. International Publication Number: WO2012/010617 A2
Gong E, Ivens T, Van den Eynde C et al (2008) Development of robust antiviral assays for profiling compounds against a panel of positive-strand RNA viruses using ATP/luminescence readout. J Virol Methods 151:121–125
Acknowledgments
The assay development presented in this chapter was sponsored by an IWT (agentschap voor Innovatie door Wetenschap en Technologie: Agency for Innovation by Science and Technology) Grant from the Flemish Government, Belgium.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Gong, E.Y., Bonfanti, JF., Ivens, T., Van der Auwera, M., Van Kerckhove, B., Kraus, G. (2013). Development of a High-Throughput Antiviral Assay for Screening Inhibitors of Chikungunya Virus and Generation of Drug-Resistant Mutations in Cultured Cells. In: Gong, E. (eds) Antiviral Methods and Protocols. Methods in Molecular Biology, vol 1030. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-484-5_32
Download citation
DOI: https://doi.org/10.1007/978-1-62703-484-5_32
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-483-8
Online ISBN: 978-1-62703-484-5
eBook Packages: Springer Protocols